Literature DB >> 2223703

Topical timolol and serum lipoproteins.

J West1, S Longstaff.   

Abstract

Oral timolol taken for the treatment of systemic hypertension has been shown to affect adversely serum lipoprotein levels. In a 15-week study on 19 patients topical timolol therapy for raised intraocular pressure was found to have no significant adverse effect on serum lipoprotein levels. This is reassuring in view of the large number of patients on this form of long term therapy, and selection of the type of beta blocker to use should not be influenced by lipid changes associated with the oral form of the drug.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2223703      PMCID: PMC1042253          DOI: 10.1136/bjo.74.11.663

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  13 in total

1.  High-density lipoprotein cholesterol and antihypertensive drugs: the Oslo study.

Authors:  A Helgeland; I Hjermann; P Leren; S Enger; I Holme
Journal:  Br Med J       Date:  1978-08-05

Review 2.  Systemic adverse reactions to glaucoma medications.

Authors:  F T Fraunfelder; S M Meyer
Journal:  Int Ophthalmol Clin       Date:  1989

3.  Ocular and cardiovascular response to topical carteolol 2% and timolol 0.5% in healthy volunteers.

Authors:  D J Brazier; S E Smith
Journal:  Br J Ophthalmol       Date:  1988-02       Impact factor: 4.638

Review 4.  Antihypertensive treatment and serum lipoproteins.

Authors:  P Weidmann; D E Uehlinger; A Gerber
Journal:  J Hypertens       Date:  1985-08       Impact factor: 4.844

5.  Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease.

Authors:  G J Miller; N E Miller
Journal:  Lancet       Date:  1975-01-04       Impact factor: 79.321

6.  Effects of diuretic and beta-blocker therapy in the Medical Research Council Trial.

Authors:  G Greenberg; P J Brennan; W E Miall
Journal:  Am J Med       Date:  1984-02-27       Impact factor: 4.965

7.  High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study.

Authors:  T Gordon; W P Castelli; M C Hjortland; W B Kannel; T R Dawber
Journal:  Am J Med       Date:  1977-05       Impact factor: 4.965

8.  The triglyceride issue: a view from Framingham.

Authors:  W P Castelli
Journal:  Am Heart J       Date:  1986-08       Impact factor: 4.749

9.  Dynamics and kinetics of ophthalmic timolol.

Authors:  M B Affrime; D T Lowenthal; J A Tobert; J Shirk; B Eidelson; T Cook; G Onesti
Journal:  Clin Pharmacol Ther       Date:  1980-04       Impact factor: 6.875

10.  Plasma timolol in glaucoma patients.

Authors:  M S Passo; E A Palmer; E M Van Buskirk
Journal:  Ophthalmology       Date:  1984-11       Impact factor: 12.079

View more
  4 in total

1.  Topical timolol and serum lipoproteins.

Authors:  D L Diehl; A L Coleman; H D Jampel; H A Quigley; P S Bachorik
Journal:  Br J Ophthalmol       Date:  1992-03       Impact factor: 4.638

2.  Topical beta blockers and serum lipoproteins.

Authors:  P W Joyce; P S Raj
Journal:  Br J Ophthalmol       Date:  1991-08       Impact factor: 4.638

3.  Topical timolol maleate might adversely affect serum lipoproteins.

Authors:  A B Safran; F Simona; A Sansonetti; D Pometta; R James
Journal:  Int Ophthalmol       Date:  1993-04       Impact factor: 2.031

Review 4.  Current concepts of pharmacotherapy in hypertension--ophthalmically administered beta blockers and their cardiopulmonary effects.

Authors:  D A Sica
Journal:  J Clin Hypertens (Greenwich)       Date:  2001 May-Jun       Impact factor: 3.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.